Evidence map›Paper›PMID 40786112›Full record

ArticlePeerJ2025

Serum β-klotho is a potential biomarker for diagnosing alcoholic liver disease and differentiating from nonalcoholic fatty liver disease.

Chengmei Fang, Xin Miao, Chuyan Peng, Zhenguo Xie, Fuzhen Zhao, Tian Chen, Wenjin Zhang, Xiaofei Bi, Xuan An, Guicheng Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chengmei Fang *Department of Infectious Disease, Southwest Medical University, Sichuan, China.
Xin Miao *Blood Transfusion Department, Chongqing University Three Gorges Hospital, Chongqing, China.
Chuyan PengChongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases, Chongqing University Three Gorges Hospital, Chongqing, China.
Zhenguo XieDepartment of Pharmacy, Chongqing University Three Gorges Hospital, Chongqing, China.
Fuzhen ZhaoSchool of Medicine, Chongqing University, Chongqing, China.
Tian ChenHealth Management Center, Chongqing University Three Gorges Hospital, Chongqing, China.
Wenjin ZhangChongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases, Chongqing University Three Gorges Hospital, Chongqing, China.
Xiaofei BiDepartment of Hepatology, Chongqing University Three Gorges Hospital, Chongqing, China.
Xuan AnChongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases, Chongqing University Three Gorges Hospital, Chongqing, China.
Guicheng WuDepartment of Infectious Disease, Southwest Medical University, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alcoholic liver disease (ALD), with the control of infectious liver disease and the improvement in living standards, is emerging as a significant liver disease posing a threat to public health. Besides, ALD often overlaps or coexists with nonalcoholic fatty liver disease (NAFLD), however, due to the lack of specific non-invasive biomarkers and the fact that drinkers' self-reported alcohol consumption is often concealed, the identification of ALD and NAFLD is sometimes not easy. This study aims to explore a new specific serum biomarker to more easily diagnose ALD and differentiate it from NAFLD. Subjects and Methods: A total of 204 serum samples were collected, including 70 from ALD patients, 68 from NAFLD patients and 66 from healthy controls (HC). Serum β-klotho (sKLB) levels were measured using the enzyme-linked immunosorbent assay (ELISA). The diagnostic performance of potential biomarkers was evaluated using the area under the receive operating characteristic curve (AUROC). Results: The levels of sKLB were significantly elevated (1,332.12 (410.40, 2,687.00) pg/mL, Conclusion: sKLB is a potential biomarker for diagnosing ALD, and may aid in differentiating between ALD and NAFLD, when combined with GGT, sKLB offers enhanced diagnostic sensitivity and specificity for ALD.

Indexed as

GlucuronidaseLiver Diseases, AlcoholicNon-alcoholic Fatty Liver DiseaseAdultBiomarkersCase-Control StudiesDiagnosis, DifferentialEnzyme-Linked Immunosorbent AssayFemaleHumansKlotho ProteinsMaleMiddle AgedROC CurveBiomarkersGlucuronidaseKlotho ProteinsKL protein, humanAlcoholic liver diseaseBiomarkerNonalcoholic fatty liver diseaseSerum β-klotho

Identifiers

PMID40786112
PMCPMC12335235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.